Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Subhash Gumber

Gastroenterology Cary, NC Medical Doctor

NPI 1205975398 CMS profile 145581

530 New Waverly Pl, Suite 200, Cary, NC 27511

Open in the dashboard

General payments

$130,464

394 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$36,727 paid to institutions, not to them · program years 2019–2021

Through program year 2023, Subhash Gumber of Cary, NC is reported in the CMS Open Payments database as having received $130,464 across 394 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,727 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $72,705 63
2022 General $52,974 113
2021 General $1,322 63
2020 General $1,656 36
2019 General $1,807 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Subhash Gumber
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Subhash Gumber were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Subhash Gumber Gastroenterology median Middle half National median
2019 $1,807 $417 $126–$1,100 $163
2020 $1,656 $224 $74–$624 $114
2021 $1,322 $352 $106–$1,054 $132
2022 $52,974 $448 $129–$1,270 $149
2023 $72,705 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Genzyme Corporation $102,488 75 payments
  2. Regeneron Healthcare Solutions, Inc. $21,470 20 payments
  3. AbbVie, Inc. $1,738 91 payments
  4. Micro-tech Endoscopy USA, Inc. $900 1 payment
  5. Pfizer Inc. $610 43 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $542 36 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $485 26 payments
  8. E.R. Squibb & Sons, L.L.C. $362 3 payments
  9. Janssen Biotech, Inc. $279 13 payments
  10. Janssen Scientific Affairs, LLC $212 2 payments
  11. Other $1,377 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $96,860 23 payments
  2. Travel and Lodging $22,052 36 payments
  3. Food and Beverage $7,932 332 payments
  4. Consulting Fee $3,520 2 payments
  5. Education $100 1 payment
Products named General payments · program years 2019–2023
  1. DUPIXENT Immunology $96,332 72 payments
  2. DUPIXENT Inflammation And Immunology $21,470 20 payments
  3. STELARA $614 23 payments
  4. HUMIRA $557 33 payments
  5. ZEPOSIA $467 9 payments
  6. CREON $449 33 payments
  7. INFLECTRA $374 25 payments
  8. SKYRIZI $340 9 payments
  9. XELJANZ $336 28 payments
  10. XIFAXAN $315 16 payments
  11. Other $2,178 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

394 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record